vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and ONESPAWORLD HOLDINGS Ltd (OSW). Click either name above to swap in a different company.
ACADIA PHARMACEUTICALS INC is the larger business by last-quarter revenue ($284.0M vs $242.1M, roughly 1.2× ONESPAWORLD HOLDINGS Ltd). ACADIA PHARMACEUTICALS INC runs the higher net margin — 96.3% vs 5.0%, a 91.3% gap on every dollar of revenue. On growth, ONESPAWORLD HOLDINGS Ltd posted the faster year-over-year revenue change (11.5% vs 9.4%). Over the past eight quarters, ACADIA PHARMACEUTICALS INC's revenue compounded faster (17.5% CAGR vs 7.1%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
ACAD vs OSW — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $284.0M | $242.1M |
| Net Profit | $273.6M | $12.1M |
| Gross Margin | 90.8% | — |
| Operating Margin | 6.1% | 6.8% |
| Net Margin | 96.3% | 5.0% |
| Revenue YoY | 9.4% | 11.5% |
| Net Profit YoY | 90.3% | -16.2% |
| EPS (diluted) | $1.61 | $0.12 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $284.0M | $242.1M | ||
| Q3 25 | $278.6M | $258.5M | ||
| Q2 25 | $264.6M | $240.7M | ||
| Q1 25 | $244.3M | $219.6M | ||
| Q4 24 | $259.6M | $217.2M | ||
| Q3 24 | $250.4M | $241.7M | ||
| Q2 24 | $242.0M | $224.9M | ||
| Q1 24 | $205.8M | $211.2M |
| Q4 25 | $273.6M | $12.1M | ||
| Q3 25 | $71.8M | $24.3M | ||
| Q2 25 | $26.7M | $19.9M | ||
| Q1 25 | $19.0M | $15.3M | ||
| Q4 24 | $143.7M | $14.4M | ||
| Q3 24 | $32.8M | $21.6M | ||
| Q2 24 | $33.4M | $15.8M | ||
| Q1 24 | $16.6M | $21.2M |
| Q4 25 | 90.8% | — | ||
| Q3 25 | 92.2% | — | ||
| Q2 25 | 92.2% | — | ||
| Q1 25 | 91.7% | — | ||
| Q4 24 | 91.6% | — | ||
| Q3 24 | 92.5% | — | ||
| Q2 24 | 92.5% | — | ||
| Q1 24 | 88.8% | — |
| Q4 25 | 6.1% | 6.8% | ||
| Q3 25 | 12.8% | 10.2% | ||
| Q2 25 | 12.2% | 9.2% | ||
| Q1 25 | 7.9% | 7.7% | ||
| Q4 24 | 59.1% | 7.9% | ||
| Q3 24 | 12.6% | 10.3% | ||
| Q2 24 | 12.6% | 8.4% | ||
| Q1 24 | 7.4% | 8.0% |
| Q4 25 | 96.3% | 5.0% | ||
| Q3 25 | 25.8% | 9.4% | ||
| Q2 25 | 10.1% | 8.3% | ||
| Q1 25 | 7.8% | 7.0% | ||
| Q4 24 | 55.4% | 6.6% | ||
| Q3 24 | 13.1% | 8.9% | ||
| Q2 24 | 13.8% | 7.0% | ||
| Q1 24 | 8.0% | 10.0% |
| Q4 25 | $1.61 | $0.12 | ||
| Q3 25 | $0.42 | $0.23 | ||
| Q2 25 | $0.16 | $0.19 | ||
| Q1 25 | $0.11 | $0.15 | ||
| Q4 24 | $0.86 | $0.13 | ||
| Q3 24 | $0.20 | $0.20 | ||
| Q2 24 | $0.20 | $0.15 | ||
| Q1 24 | $0.10 | $0.21 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.7M | $16.3M |
| Total DebtLower is stronger | — | $84.0M |
| Stockholders' EquityBook value | $1.2B | $542.6M |
| Total Assets | $1.6B | $707.1M |
| Debt / EquityLower = less leverage | — | 0.15× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $177.7M | $16.3M | ||
| Q3 25 | $258.0M | $29.6M | ||
| Q2 25 | $253.6M | $35.0M | ||
| Q1 25 | $217.7M | $22.6M | ||
| Q4 24 | $319.6M | $57.4M | ||
| Q3 24 | $155.1M | $48.8M | ||
| Q2 24 | $177.1M | $62.5M | ||
| Q1 24 | $204.7M | $65.4M |
| Q4 25 | — | $84.0M | ||
| Q3 25 | — | $85.2M | ||
| Q2 25 | — | $96.2M | ||
| Q1 25 | — | $97.4M | ||
| Q4 24 | — | $98.6M | ||
| Q3 24 | — | $98.7M | ||
| Q2 24 | — | $123.8M | ||
| Q1 24 | — | $138.6M |
| Q4 25 | $1.2B | $542.6M | ||
| Q3 25 | $917.3M | $552.8M | ||
| Q2 25 | $822.4M | $548.3M | ||
| Q1 25 | $765.2M | $530.6M | ||
| Q4 24 | $732.8M | $554.5M | ||
| Q3 24 | $577.2M | $540.1M | ||
| Q2 24 | $516.7M | $532.7M | ||
| Q1 24 | $464.0M | $515.5M |
| Q4 25 | $1.6B | $707.1M | ||
| Q3 25 | $1.3B | $732.6M | ||
| Q2 25 | $1.2B | $731.8M | ||
| Q1 25 | $1.1B | $708.7M | ||
| Q4 24 | $1.2B | $746.4M | ||
| Q3 24 | $976.9M | $734.0M | ||
| Q2 24 | $914.1M | $756.8M | ||
| Q1 24 | $855.1M | $763.6M |
| Q4 25 | — | 0.15× | ||
| Q3 25 | — | 0.15× | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | — | 0.18× | ||
| Q4 24 | — | 0.18× | ||
| Q3 24 | — | 0.18× | ||
| Q2 24 | — | 0.23× | ||
| Q1 24 | — | 0.27× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.7M | $20.0M |
| Free Cash FlowOCF − Capex | — | $14.9M |
| FCF MarginFCF / Revenue | — | 6.2% |
| Capex IntensityCapex / Revenue | — | 2.1% |
| Cash ConversionOCF / Net Profit | -0.18× | 1.65× |
| TTM Free Cash FlowTrailing 4 quarters | — | $68.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-48.7M | $20.0M | ||
| Q3 25 | $74.3M | $33.2M | ||
| Q2 25 | $64.0M | $20.3M | ||
| Q1 25 | $20.3M | $10.1M | ||
| Q4 24 | $40.4M | $16.6M | ||
| Q3 24 | $63.2M | $28.6M | ||
| Q2 24 | $25.0M | $18.7M | ||
| Q1 24 | $29.1M | $15.0M |
| Q4 25 | — | $14.9M | ||
| Q3 25 | $73.9M | $27.6M | ||
| Q2 25 | — | $17.6M | ||
| Q1 25 | — | $8.4M | ||
| Q4 24 | — | $13.2M | ||
| Q3 24 | $63.2M | $27.5M | ||
| Q2 24 | — | $17.6M | ||
| Q1 24 | — | $13.7M |
| Q4 25 | — | 6.2% | ||
| Q3 25 | 26.5% | 10.7% | ||
| Q2 25 | — | 7.3% | ||
| Q1 25 | — | 3.8% | ||
| Q4 24 | — | 6.1% | ||
| Q3 24 | 25.2% | 11.4% | ||
| Q2 24 | — | 7.8% | ||
| Q1 24 | — | 6.5% |
| Q4 25 | — | 2.1% | ||
| Q3 25 | 0.1% | 2.2% | ||
| Q2 25 | — | 1.1% | ||
| Q1 25 | — | 0.8% | ||
| Q4 24 | — | 1.5% | ||
| Q3 24 | 0.0% | 0.5% | ||
| Q2 24 | — | 0.5% | ||
| Q1 24 | — | 0.6% |
| Q4 25 | -0.18× | 1.65× | ||
| Q3 25 | 1.03× | 1.36× | ||
| Q2 25 | 2.40× | 1.02× | ||
| Q1 25 | 1.07× | 0.66× | ||
| Q4 24 | 0.28× | 1.15× | ||
| Q3 24 | 1.93× | 1.33× | ||
| Q2 24 | 0.75× | 1.19× | ||
| Q1 24 | 1.76× | 0.71× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACAD
| Nuplazid | $174.4M | 61% |
| Daybue | $109.6M | 39% |
OSW
| Services | $197.3M | 82% |
| Products | $44.8M | 18% |
